Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2024.65.424
Transcatheter aortic valve implantation in the first 500 patients: a single-center retrospective study
Marko Noc
; MC Medicor International Center for Cardiovascular Diseases, Izola, Slovenia
*
Ales Pleskovic
; MC Medicor International Center for Cardiovascular Diseases, Izola, Slovenia
Maja Rojko
; MC Medicor International Center for Cardiovascular Diseases, Izola, Slovenia
Hrvoje Reschner
; MC Medicor International Center for Cardiovascular Diseases, Izola, Slovenia
Natasa Cernic
; General Hospital Izola, Izola, Slovenia
Branko Cveticanin
; General Hospital Izola, Izola, Slovenia
Matjaz Span
; MC Medicor International Center for Cardiovascular Diseases, Izola, Slovenia
Stamenko Susak
; MC Medicor International Center for Cardiovascular Diseases, Izola, Slovenia
Rok Stopar
; MC Medicor International Center for Cardiovascular Diseases, Izola, Slovenia
Danijel Petrovic
; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Naomi Ana Noc
; MC Medicor International Center for Cardiovascular Diseases, Izola, Slovenia
Ana Bosnjak
; MC Medicor International Center for Cardiovascular Diseases, Izola, Slovenia
Nenad Danojevic
; MC Medicor International Center for Cardiovascular Diseases, Izola, Slovenia
Miladin Djordjevic
; MC Medicor International Center for Cardiovascular Diseases, Izola, Slovenia
Metka Zorc
; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
* Dopisni autor.
Sažetak
Aim To determine the procedural characteristics, results,
and long-term outcomes of the first 500 consecutive pa
-
tients undergoing transcatheter aortic valve implantation
(TAVI) at the MC Medicor International Center for Cardio
-
vascular Diseases Izola (Slovenia).
Methods Data were collected from the institutional reg
-
istry. The date of death was obtained from the National
BIRPIS system by using the patient’s health insurance card
number. The difference in 30-day mortality was assessed
between two consecutive cohorts of 250 patients, patients
who received self-expandable (SEV) and those with bal
-
loon-expandable (BEV) valves, and between patients ≤80
and >80 years old.
Results Between December 2016 and September
2023, 500 patients (80
±6 years, 52% men, EuroScore II,
4.09
±4.11), including 3.2% with degenerated surgical
prosthesis, underwent TAVI. After predilatation (57%), SEV
was implanted in 87.5% and BEV in 12.5% of the patients.
The mean postprocedural gradient was 10
±4 mm Hg, with
more than moderate regurgitation in 0.4%. Emergency car
-
diac/vascular surgery was performed in 1.4%, and stroke
occurred in 0.8%. The new permanent pacemaker (PPM)
rate decreased from 19% to 7% (
P
<0.001) in the second
cohort, and the mean postprocedural transaortic gradient
was significantly lower after SEV compared with BEV (9
±4
vs 13
±4 mm Hg;
P
<0.001). There was no difference in 30-
day mortality between the first and second cohort of 250
patients (1.2% vs 1.2%;
P
=1.000), cohorts of 50 patients
from number 0 to 500 (0% vs 2.0%;
P
=0.391), SEV and BEV
groups (0.9% vs 1.6%;
P
=0.487), and patients ≤80 and >80
years old (2.0% vs 0.4%;
P
=0.119).
Conclusion TAVI results in our study are comparable with
international standards. PPM rate decreased over time,
and postprocedural gradient was lower after SEV. Learning
curve, type of valve, and patient age did not affect 30-day
mortality
Ključne riječi
Hrčak ID:
336575
URI
Datum izdavanja:
15.10.2024.
Posjeta: 248 *